These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Raja SG Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803 [TBL] [Abstract][Full Text] [Related]
6. Role of Rho-kinase and its inhibitors in pulmonary hypertension. Duong-Quy S; Bei Y; Liu Z; Dinh-Xuan AT Pharmacol Ther; 2013 Mar; 137(3):352-64. PubMed ID: 23261521 [TBL] [Abstract][Full Text] [Related]
7. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension. Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956 [TBL] [Abstract][Full Text] [Related]
8. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Barman SA; Zhu S; White RE Vasc Health Risk Manag; 2009; 5():663-71. PubMed ID: 19707285 [TBL] [Abstract][Full Text] [Related]
9. Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension. Oka M; Homma N; McMurtry IF Methods Enzymol; 2008; 439():191-204. PubMed ID: 18374166 [TBL] [Abstract][Full Text] [Related]
10. Development of Rho-kinase inhibitors for cardiovascular medicine. Shimokawa H; Rashid M Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681 [TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for the treatment of pulmonary hypertension. Stenmark KR; Rabinovitch M Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S85-90. PubMed ID: 20216170 [TBL] [Abstract][Full Text] [Related]
15. Rho-kinase is an important therapeutic target in cardiovascular medicine. Shimokawa H; Takeshita A Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741 [TBL] [Abstract][Full Text] [Related]
16. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Guan R; Xu X; Chen M; Hu H; Ge H; Wen S; Zhou S; Pi R Eur J Med Chem; 2013; 70():613-22. PubMed ID: 24211637 [TBL] [Abstract][Full Text] [Related]
17. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. Berghausen E; ten Freyhaus H; Rosenkranz S Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349 [TBL] [Abstract][Full Text] [Related]
18. Stepwise high-throughput virtual screening of Rho kinase inhibitors from natural product library and potential therapeutics for pulmonary hypertension. Su H; Yan J; Xu J; Fan XZ; Sun XL; Chen KY Pharm Biol; 2015 Aug; 53(8):1201-6. PubMed ID: 25853972 [TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate for the treatment of pulmonary arterial hypertension. ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410 [TBL] [Abstract][Full Text] [Related]
20. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Do e Z; Fukumoto Y; Takaki A; Tawara S; Ohashi J; Nakano M; Tada T; Saji K; Sugimura K; Fujita H; Hoshikawa Y; Nawata J; Kondo T; Shimokawa H Circ J; 2009 Sep; 73(9):1731-9. PubMed ID: 19590140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]